Characterization of the SARS-CoV-2 B.1.621 (Mu) variant.
Journal
Science translational medicine
ISSN: 1946-6242
Titre abrégé: Sci Transl Med
Pays: United States
ID NLM: 101505086
Informations de publication
Date de publication:
10 08 2022
10 08 2022
Historique:
pubmed:
18
5
2022
medline:
13
8
2022
entrez:
17
5
2022
Statut:
ppublish
Résumé
The SARS-CoV-2 B.1.621 (Mu) variant emerged in January 2021 and was categorized as a variant of interest by the World Health Organization in August 2021. This designation prompted us to study the sensitivity of this variant to antibody neutralization. In a live virus neutralization assay with serum samples from individuals vaccinated with the Pfizer/BioNTech or Moderna mRNA vaccines, we measured neutralization antibody titers against B.1.621, an early isolate (spike 614D), and a variant of concern (B.1.351, Beta variant). We observed reduced neutralizing antibody titers against the B.1.621 variant (3.4- to 7-fold reduction, depending on the serum sample and time after the second vaccination) compared to the early isolate and a similar reduction when compared to B.1.351. Likewise, convalescent serum from hamsters previously infected with an early isolate neutralized B.1.621 to a lower degree. Despite this antibody titer reduction, hamsters could not be efficiently rechallenged with the B.1.621 variant, suggesting that the immune response to the first infection is adequate to provide protection against a subsequent infection with the B.1.621 variant.
Identifiants
pubmed: 35579540
doi: 10.1126/scitranslmed.abm4908
pmc: PMC9392899
mid: NIHMS1827712
doi:
Substances chimiques
Antibodies, Neutralizing
0
Antibodies, Viral
0
Membrane Glycoproteins
0
Spike Glycoprotein, Coronavirus
0
Viral Envelope Proteins
0
spike protein, SARS-CoV-2
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
eabm4908Subventions
Organisme : NIAID NIH HHS
ID : 75N93019C00051
Pays : United States
Organisme : NIAID NIH HHS
ID : HHSN272201400008C
Pays : United States
Organisme : NIAID NIH HHS
ID : P01 AI131251
Pays : United States
Organisme : NIH HHS
ID : P51 OD011106
Pays : United States
Références
Nat Commun. 2021 Aug 26;12(1):5135
pubmed: 34446720
Cell. 2020 Aug 20;182(4):812-827.e19
pubmed: 32697968
Cell Host Microbe. 2021 Mar 10;29(3):463-476.e6
pubmed: 33592168
Cell Host Microbe. 2021 Apr 14;29(4):516-521.e3
pubmed: 33798491
Proc Natl Acad Sci U S A. 2020 Jul 14;117(28):16587-16595
pubmed: 32571934
Cell. 2021 Apr 29;184(9):2348-2361.e6
pubmed: 33730597
J Med Virol. 2021 Dec;93(12):6468-6470
pubmed: 34329486
Sci Transl Med. 2021 Jun 30;13(600):
pubmed: 34103407
Signal Transduct Target Ther. 2021 Jul 27;6(1):284
pubmed: 34315847
Nat Commun. 2021 Jul 7;12(1):4196
pubmed: 34234131
mBio. 2021 Jan 19;12(1):
pubmed: 33468695
Immunity. 2021 Jul 13;54(7):1611-1621.e5
pubmed: 34166623
Infect Genet Evol. 2021 Nov;95:105038
pubmed: 34403832
Proc Natl Acad Sci U S A. 2020 Mar 31;117(13):7001-7003
pubmed: 32165541
Cell Host Microbe. 2021 May 12;29(5):819-833.e7
pubmed: 33789084
Nature. 2020 Jul;583(7818):834-838
pubmed: 32408338
Elife. 2021 Aug 20;10:
pubmed: 34414884
Cell. 2021 Apr 29;184(9):2332-2347.e16
pubmed: 33761326
EBioMedicine. 2021 Sep;71:103544
pubmed: 34419925